The UK government has unveiled a £75 million strategy aimed at accelerating the phase-out of animal testing in scientific research, promoting alternatives such as organ-on-a-chip systems, artificial intelligence modelling, and 3D bioprinted human tissues. Science Minister Lord Vallance described the initiative on Tuesday as a “roadmap for innovation and compassion” that will help the UK lead globally in non-animal testing methods.
The plan sets out clear milestones for replacing animal experiments across several areas. By the end of 2026, tests for skin and eye irritation and skin sensitisation will no longer involve animals. In 2027, DNA-based methods will replace tests on mice for Botox potency and certain human medicine contamination checks. By 2030, the use of dogs and non-human primates in pharmacokinetic studies, which track how drugs move through the body, will be sharply reduced.
Funding will support two national hubs: one focused on fostering collaboration and data sharing among researchers, and another dedicated to streamlining regulatory approval for new non-animal testing methods. An additional £15.9 million from the Medical Research Council, Innovate UK, and the Wellcome Trust will back “human in vitro” disease models, targeting research on the liver, brain, cancer, pain, and blood vessels.
Lord Vallance said the strategy “will end animal testing wherever possible and roll out alternatives as soon as it is safe and effective to do so.” Animal Welfare Minister Baroness Hayman called it “a major step forward for animal welfare and scientific innovation.”
The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) will lead the implementation. Chief executive Dr Vicky Robinson said the roadmap is “ambitious” and essential for maintaining the UK’s global leadership in ethical science.
The announcement has been welcomed by both scientific and animal welfare communities. The RSPCA described it as a “clear ambition towards eliminating animal use,” while the Association of the British Pharmaceutical Industry (ABPI) highlighted the plan’s balance between advancing humane science and maintaining patient safety.
Experts stressed that some animal research will remain necessary until alternatives are fully validated. Dr Nicola Perrin, chief executive of the Association of Medical Research Charities, noted, “It’s important that we continue to use animals where no other options are available, while doing everything possible to advance alternatives.”
A cross-departmental committee chaired by Lord Vallance will oversee the strategy, with performance indicators to be published next year to track progress. If implemented successfully, the plan could position the UK as a global leader in ethical, high-tech bioscience, achieving breakthroughs in medicine while making animal testing increasingly obsolete.
